Nes-Ziona, Israel, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd., (NASDAQ:ENLV, the "Company"))), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the U.S. Patent and Trademark Office issued a new patent, number US 11,883,429, covering AllocetraTM, the Company's immunotherapy product candidate. The new patent is expected to provide added intellectual property protection in the United States for the product's composition and manufacturing method. ABOUT ENLIV ...

Exhibit 99.1 ENLIVEX THERAPEUTICS LTD. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF SEPTEMBER 30, 2023 AND DECEMBER 31, 2022 AND FOR THE THREE AND NINE MONTH PERIODS ENDED SEPTEMBER 30, 2023 AND 2022 ENLIVEX THERAPEUTICS LTD. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF SEPTEMBER 30, 2023 AND DECEMBER 31, 2022 AND FOR THE THREE AND NINE MONTH PERIODS ENDED SEPTEMBER 30, 2023 AND 2022 INDEX TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS | | Page | | --- | --- | | Condensed Consolidated Balance Shee ...

Exhibit 99.1 ENLIVEX THERAPEUTICS LTD. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF MARCH 31, 2023 AND DECEMBER 31, 2022 AND FOR THE THREE MONTH PERIODS ENDED MARCH 31, 2023 AND 2022 ENLIVEX THERAPEUTICS LTD. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF MARCH 31, 2023 AND DECEMBER 31, 2022 AND FOR THE THREE MONTH PERIODS ENDED MARCH 31, 2023 AND 2022 INDEX TO CONSOLIDATED FINANCIAL STATEMENTS | | Page | | --- | --- | | Condensed Consolidated Balance Sheets | F-1 | | Condensed Consolidated Statemen ...

| --- | --- | |-------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------| | The problem: | The primary reason: | | Too many patients with life- threatening diseases do not respond to existing therapies | The most prevalent life- threatening diseases involve multiple pathways of the immune system, making them highly evasive | Sepsis is the 3rd leading ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of event requiring this shell company report For the transition period from ____ to ____ Commission file number 001-36578 Enlivex Therapeutics Ltd. (Exact name of Registrant as specified in its charter) OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ende ...

Exhibit 99.1 ENLIVEX THERAPEUTICS LTD. FINANCIAL STATEMENTS AS OF DECEMBER 31, 2022 ENLIVEX THERAPEUTICS LTD. FINANCIAL STATEMENTS AS OF DECEMBER 31, 2022 INDEX | | Page | | --- | --- | | Report of Independent Registered Public Accounting Firm | F-2 | | Consolidated Balance Sheets | F-3 | | Consolidated Statements of Operations and Comprehensive Loss | F-4 | | Consolidated Statements of Changes in Shareholders' Equity | F-5 | | Consolidated Statements of Cash Flows | F-6 | | Notes to Consolidated Financial ...

Exhibit 99.1 ENLIVEX THERAPEUTICS LTD. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF SEPTEMBER 30, 2022 AND DECEMBER 31, 2021 AND FOR THE THREE AND NINE MONTH PERIODS ENDED SEPTEMBER 30, 2022 AND 2021 ENLIVEX THERAPEUTICS LTD. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF SEPTEMBER 30, 2022 AND DECEMBER 31, 2021 AND FOR THE THREE AND NINE MONTH PERIODS ENDED SEPTEMBER 30, 2022 AND 2021 INDEX TO CONSOLIDATED FINANCIAL STATEMENTS | --- | --- | |--------------------------------------------------------- ...

| --- | --- | |-------------------------------------------------------------------------------|-------| | | | | | | | | | | | | | | | | Off-the-shelf, universal, macrophage reprogramming cell therapies for life- | | | threatening diseases NASDAQ Ticker: ENLV | | Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements and information. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our ...

Exhibit 99.1 ENLIVEX THERAPEUTICS LTD. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF MARCH 31, 2022 AND DECEMBER 31, 2021 AND FOR THE THREE MONTH PERIODS ENDED MARCH 31, 2022 AND 2021 ENLIVEX THERAPEUTICS LTD. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF MARCH 31, 2022 AND DECEMBER 31, 2021 AND FOR THE THREE MONTH PERIODS ENDED MARCH 31, 2022 AND 2021 INDEX TO CONSOLIDATED FINANCIAL STATEMENTS Page | --- | --- | |-------------------------------------------------------------------------------------- ...

Exhibit 99.1 Enlivex Announces Full Year 2021 Financial Results, Completion of Development of Frozen Formulation Allocetra™ Ahead of Schedule, and Provides Strategic & Business Updates ● Development of frozen formulation Allocetra™, a primary cornerstone of Enlivex's R&D ef orts during the last two years, was successfully completed in Q1 2022, twelve months ahead of schedule ● Frozen formulation Allocetra™ is expected to vastly improve the product's shelf-life, shipping logistics, and manufacturing scalabil ...